{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:07:29Z","timestamp":1792757249775,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40263-016-0374-z","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T11:01:12Z","timestamp":1469703672000},"page":"1111-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Treatment for Rheumatoid Arthritis and Risk of Alzheimer\u2019s Disease: A Nested Case-Control Analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Richard C.","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"issue":"3","key":"374_CR1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","volume":"11","author":"Alzheimer's Association","year":"2015","unstructured":"Alzheimer's Association. 2015 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2015;11(3):332\u201384.","journal-title":"Alzheimers Dement."},{"issue":"19","key":"374_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census. Neurology. 2013;80(19):1778\u201383. doi: 10.1212\/WNL.0b013e31828726f5 .","journal-title":"Neurology."},{"issue":"4","key":"374_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/YCO.0b013e32816ebc7b","volume":"20","author":"C Qiu","year":"2007","unstructured":"Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry. 2007;20(4):380\u20135. doi: 10.1097\/YCO.0b013e32816ebc7b .","journal-title":"Curr Opin Psychiatry."},{"key":"374_CR4","doi-asserted-by":"publisher","unstructured":"Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8). doi: 10.1101\/cshperspect.a006239 .","DOI":"10.1101\/cshperspect.a006239"},{"issue":"12","key":"374_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138. doi: 10.1038\/ng.2802 .","journal-title":"Nat Genet."},{"issue":"6","key":"374_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u201372. doi: 10.1038\/nrn3880 .","journal-title":"Nat Rev Neurosci."},{"issue":"6","key":"374_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d. Clin Anat. 1995;8(6):429\u201331. doi: 10.1002\/ca.980080612 .","journal-title":"Clin Anat."},{"key":"374_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1192\/bjp.35.150.261","volume":"35","author":"S Beljahow","year":"1889","unstructured":"Beljahow S. Pathological changes in the brain in dementia senilis. J Ment Sci. 1889;35:261\u20132.","journal-title":"J Ment Sci."},{"key":"374_CR9","first-page":"221","volume":"31","author":"T Simchowicz","year":"1924","unstructured":"Simchowicz T. Sur la signification des plaques seniles et sur la formule senile de l`ecorce cerebrale. Rev Neurol. 1924;31:221\u20137.","journal-title":"Rev Neurol."},{"issue":"3","key":"374_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","volume":"126","author":"L Gu","year":"2013","unstructured":"Gu L, Guo Z. Alzheimer\u2019s Abeta42 and Abeta40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126(3):305\u201311. doi: 10.1111\/jnc.12202 .","journal-title":"J Neurochem."},{"issue":"13","key":"374_CR11","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","volume":"270","author":"SA Gravina","year":"1995","unstructured":"Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer\u2019s disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995;270(13):7013\u20136.","journal-title":"J Biol Chem."},{"issue":"3","key":"374_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ana.410370303","volume":"37","author":"SG Younkin","year":"1995","unstructured":"Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer\u2019s disease. Ann Neurol. 1995;37(3):287\u20138. doi: 10.1002\/ana.410370303 .","journal-title":"Ann Neurol."},{"issue":"7355","key":"374_CR13","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/475S8a","volume":"475","author":"NS Buckholtz","year":"2011","unstructured":"Buckholtz NS. Perspective: in search of biomarkers. Nature. 2011;475(7355):S8. doi: 10.1038\/475S8a .","journal-title":"Nature."},{"key":"374_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;. doi: 10.1016\/S0140-6736(15)01124-1 .","journal-title":"Lancet."},{"issue":"3","key":"374_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. doi: 10.1016\/j.jalz.2011.03.005 .","journal-title":"Alzheimers Dement."},{"issue":"3","key":"374_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. doi: 10.1016\/j.jalz.2011.03.008 .","journal-title":"Alzheimers Dement."},{"issue":"3","key":"374_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. doi: 10.1016\/j.jalz.2011.03.003 .","journal-title":"Alzheimers Dement."},{"issue":"4","key":"374_CR18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1020568013953","volume":"19","author":"E Tarkowski","year":"1999","unstructured":"Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19(4):223\u201330.","journal-title":"J Clin Immunol."},{"issue":"9","key":"374_CR19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.74.9.1200","volume":"74","author":"E Tarkowski","year":"2003","unstructured":"Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer\u2019s disease. J Neurol Neurosurg Pychiatry. 2003;74(9):1200\u20135.","journal-title":"J Neurol Neurosurg Pychiatry."},{"issue":"2","key":"374_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","volume":"50","author":"F Brosseron","year":"2014","unstructured":"Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: a comparative overview. Mol Neurobiol. 2014;50(2):534\u201344. doi: 10.1007\/s12035-014-8657-1 .","journal-title":"Mol Neurobiol."},{"issue":"11","key":"374_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359\u201362. doi: 10.1038\/nm1653 .","journal-title":"Nat Med."},{"issue":"10","key":"374_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10):768\u201374. doi: 10.1212\/WNL.0b013e3181b6bb95 .","journal-title":"Neurology."},{"issue":"11","key":"374_CR23","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537\u201345. doi: 10.1172\/JCI36389 .","journal-title":"J Clin Invest."},{"issue":"23","key":"374_CR24","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra100496510.7748\/phc2011.11.21.9.29.c8797","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2011;365(23):2205\u201319. doi: 10.1056\/NEJMra100496510.7748\/phc2011.11.21.9.29.c8797 .","journal-title":"New Engl J Med."},{"issue":"1","key":"374_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","volume":"12","author":"IB McInnes","year":"2016","unstructured":"McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis: shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63\u20138. doi: 10.1038\/nrrheum.2015.171 .","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"374_CR26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002281-200101000-00011","volume":"13","author":"G Cunnane","year":"2001","unstructured":"Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001;13(1):67\u201373.","journal-title":"Curr Opin Rheumatol."},{"key":"374_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2015","unstructured":"Westermark GT, Fandrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Ann Rev Pathol. 2015;10:321\u201344. doi: 10.1146\/annurev-pathol-020712-163913 .","journal-title":"Ann Rev Pathol."},{"issue":"13","key":"374_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898\u2013909. doi: 10.1056\/NEJM199709253371306 .","journal-title":"N Engl J Med."},{"issue":"1","key":"374_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jclinepi.2004.04.013","volume":"58","author":"G Corrao","year":"2005","unstructured":"Corrao G, Zambon A, Faini S, Bagnardi V, Leoni O, Suissa S. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol. 2005;58(1):92\u20137. doi: 10.1016\/j.jclinepi.2004.04.013 .","journal-title":"J Clin Epidemiol."},{"issue":"7","key":"374_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","volume":"46","author":"S Bernatsky","year":"2007","unstructured":"Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1157\u201360. doi: 10.1093\/rheumatology\/kem076 .","journal-title":"Rheumatology (Oxford)."},{"key":"374_CR31","doi-asserted-by":"publisher","unstructured":"Rose S, Laan MJ. Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat. 2009;5(1):Article 1. doi: 10.2202\/1557-4679.1127 .","DOI":"10.2202\/1557-4679.1127"},{"issue":"11","key":"374_CR32","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"IB McInnes","year":"2010","unstructured":"McInnes IB, O\u2019Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69(11):1898\u2013906. doi: 10.1136\/ard.2010.134684 .","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"374_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58(1):15\u201325. doi: 10.1002\/art.23177 .","journal-title":"Arthritis Rheum."},{"issue":"1","key":"374_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2009.12.009","volume":"35","author":"GJ Tobon","year":"2010","unstructured":"Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: eheumatoid arthritis. J Autoimmun. 2010;35(1):10\u20134. doi: 10.1016\/j.jaut.2009.12.009 .","journal-title":"J Autoimmun."},{"issue":"5","key":"374_CR35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1358\/mf.2004.26.5.831324","volume":"26","author":"S Appenzeller","year":"2004","unstructured":"Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheumatoid arthritis. Methods Find Exp Clin Pharmacol. 2004;26(5):339\u201343.","journal-title":"Methods Find Exp Clin Pharmacol."},{"issue":"Pt 5","key":"374_CR36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/brain\/awu043","volume":"137","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, et al. Association of brain amyloid-beta with cerebral perfusion and structure in Alzheimer\u2019s disease and mild cognitive impairment. Brain. 2014;137(Pt 5):1550\u201361. doi: 10.1093\/brain\/awu043 .","journal-title":"Brain."},{"issue":"9","key":"374_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1212\/01.wnl.0000210447.19748.0b","volume":"66","author":"MS Beeri","year":"2006","unstructured":"Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 2006;66(9):1399\u2013404. doi: 10.1212\/01.wnl.0000210447.19748.0b .","journal-title":"Neurology."},{"issue":"13","key":"374_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1212\/WNL.0b013e3181f4d7f8","volume":"75","author":"S Ahtiluoto","year":"2010","unstructured":"Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195\u2013202. doi: 10.1212\/WNL.0b013e3181f4d7f8 .","journal-title":"Neurology."},{"issue":"9","key":"374_CR39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.49.9.665","volume":"49","author":"C Tetta","year":"1990","unstructured":"Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49(9):665\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"374_CR40","doi-asserted-by":"publisher","first-page":"e60635","DOI":"10.1371\/journal.pone.0060635","volume":"8","author":"M Centola","year":"2013","unstructured":"Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635. doi: 10.1371\/journal.pone.0060635 .","journal-title":"PLoS One."},{"issue":"2\u20133","key":"374_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neulet.2008.09.044","volume":"446","author":"A Tedde","year":"2008","unstructured":"Tedde A, Putignano AL, Nacmias B, Bagnoli S, Cellini E, Sorbi S. Lack of association between TNF-alpha polymorphisms and Alzheimer\u2019s disease in an Italian cohort. Neurosci Lett. 2008;446(2\u20133):139\u201342. doi: 10.1016\/j.neulet.2008.09.044 .","journal-title":"Neurosci Lett."},{"issue":"4","key":"374_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jbspin.2010.01.017","volume":"77","author":"YM Chen","year":"2010","unstructured":"Chen YM, Chen HH, Lan JL, Chen DY. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Jt Bone Spine. 2010;77(4):366\u20137. doi: 10.1016\/j.jbspin.2010.01.017 .","journal-title":"Jt Bone Spine."},{"issue":"4","key":"374_CR43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/156720507781788873","volume":"4","author":"D Tweedie","year":"2007","unstructured":"Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4(4):378\u201385.","journal-title":"Curr Alzheimer Res."},{"key":"374_CR44","doi-asserted-by":"publisher","unstructured":"Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener\u2019s granulomatosis. Ann Rheum Dis. 2005;64 Suppl 4:iv31\u20136. doi: 10.1136\/ard.2005.042416 .","DOI":"10.1136\/ard.2005.042416"},{"issue":"15","key":"374_CR45","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease: Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029\u201335. doi: 10.1056\/NEJM199710093371502 .","journal-title":"N Engl J Med."},{"issue":"4","key":"374_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med. 2005;352(4):351\u201361. doi: 10.1056\/NEJMoa041884 .","journal-title":"N Engl J Med."},{"issue":"1","key":"374_CR47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","volume":"116","author":"FJ Baert","year":"1999","unstructured":"Baert FJ, D\u2019Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis. Gastroenterology. 1999;116(1):22\u20138.","journal-title":"Gastroenterology."},{"issue":"2","key":"374_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","volume":"131","author":"Z Kaymakcalan","year":"2009","unstructured":"Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308\u201316. doi: 10.1016\/j.clim.2009.01.002 .","journal-title":"Clin Immunol."},{"issue":"3","key":"374_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","volume":"44","author":"S Mpofu","year":"2005","unstructured":"Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren\u2019t they?). Rheumatology (Oxford). 2005;44(3):271\u20133. doi: 10.1093\/rheumatology\/keh483 .","journal-title":"Rheumatology (Oxford)."},{"issue":"21","key":"374_CR50","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"J Butchart","year":"2015","unstructured":"Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161\u20138. doi: 10.1212\/WNL.0000000000001617 .","journal-title":"Neurology."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0374-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0374-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0374-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T17:29:47Z","timestamp":1568222987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0374-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0374-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}